My Treatment Approach: Androgen Receptor Inhibitors and the Evolving Treatment Paradigm in Castration-Sensitive Prostate Cancer - Episode 3
Evolving Treatment Paradigm and NCCN Guideline Updates
Key opinion leaders examine the treatment landscape for castration-sensitive prostate cancer, highlighting prevalent first-line approaches and discussing the role of androgen deprivation therapy in the treatment paradigm.
- Dr. Freedland asks Dr. Efstathiou: Please review the current treatment landscape for CSPC. What are the main therapeutic approaches typically utilized for these patients?
- What role does androgen deprivation therapy alone play, and in what settings?
- When are chemotherapy and novel hormonal agents like enzalutamide considered?
- How do you sequence or combine these different modalities in your practice?
- Dr. Efstathiou asks Dr. Freedland:The NCCN guidelines were recently updated to include enzalutamide as a treatment option for high-risk non-metastatic CSPC and metastatic CSPC, as well as metastatic and nonmetastatic CRPC. Can you summarize the significance of these updates?
- How do you see these guideline changes impacting clinical practice patterns?
Related Content:
